Hadasit Bio (HDST) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hadasit Bio (HDST) has a cash flow conversion efficiency ratio of -0.009x as of June 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-360.50K ≈ $-966.49 USD) by net assets (ILA39.81 Million ≈ $106.73K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hadasit Bio - Cash Flow Conversion Efficiency Trend (2013–2022)
This chart illustrates how Hadasit Bio's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Hadasit Bio total liabilities for a breakdown of total debt and financial obligations.
Hadasit Bio Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hadasit Bio ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UIL Ltd
LSE:UTL
|
0.057x |
|
PBS Finanse SA
WAR:PBF
|
-0.096x |
|
Jadestone Energy Inc
LSE:JSE
|
-0.014x |
|
WINDFALL GEOTEK
F:L7C2
|
-0.801x |
|
Sungmoon Electronics Co Ltd
KO:014915
|
0.037x |
|
Stinger Resources Inc
V:STNG
|
-0.044x |
|
Key Alliance Group Bhd
KLSE:0036
|
1.245x |
|
Lucapa Diamond Co Ltd
F:NHY
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Hadasit Bio (2013–2022)
The table below shows the annual cash flow conversion efficiency of Hadasit Bio from 2013 to 2022. For the full company profile with market capitalisation and key ratios, see market value of Hadasit Bio.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | ILA35.08 Million ≈ $94.04K |
ILA-2.12 Million ≈ $-5.67K |
-0.060x | -88.52% |
| 2021-12-31 | ILA65.69 Million ≈ $176.12K |
ILA-2.10 Million ≈ $-5.63K |
-0.032x | +70.05% |
| 2020-12-31 | ILA37.11 Million ≈ $99.49K |
ILA-3.96 Million ≈ $-10.62K |
-0.107x | +81.53% |
| 2019-12-31 | ILA5.50 Million ≈ $14.75K |
ILA-3.18 Million ≈ $-8.53K |
-0.578x | -20.50% |
| 2018-12-31 | ILA34.30 Million ≈ $91.96K |
ILA-16.46 Million ≈ $-44.12K |
-0.480x | -65.93% |
| 2017-12-31 | ILA60.79 Million ≈ $162.97K |
ILA-17.57 Million ≈ $-47.12K |
-0.289x | -21.36% |
| 2016-12-31 | ILA61.62 Million ≈ $165.20K |
ILA-14.68 Million ≈ $-39.36K |
-0.238x | -8.35% |
| 2015-12-31 | ILA60.30 Million ≈ $161.66K |
ILA-13.26 Million ≈ $-35.55K |
-0.220x | +60.29% |
| 2014-12-31 | ILA22.11 Million ≈ $59.28K |
ILA-12.24 Million ≈ $-32.82K |
-0.554x | -18.68% |
| 2013-12-31 | ILA24.89 Million ≈ $66.72K |
ILA-11.61 Million ≈ $-31.13K |
-0.467x | -- |
About Hadasit Bio
HBL - Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It operates in the fields of oncology, regenerative medicine, and inflammatory disease. The company develops biological drugs; and plasma RNA biomarkers for colorectal cancer. It offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. HBL - Hadasit Bio-Holdings L… Read more